In addition to prolonged OS after treatment with ICIs, NCOR1 mutations were associated with higher tumor immunogenicity, activated antitumor immunity, a number of mutations in the DDR pathway, immune cells and upregulated expression of immune-related genes. This evidence concerns the gene NCOR1 and neoplasm.